Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00006345
Completed
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2013
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Register for Updates
Treatment of Acute Lymphoblastic Leukemia in Children
NCT00165178
Completed
The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/23/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
NCT00530270
Terminated
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization. Dexamethasone is a medication that may decrease hospitalization time for people with ACS, but it may also bring about new sickle cell pain. This study will evaluate the effectiveness of a dexamethasone regimen that includes a gradual dose reduction at decreasing hospitalization and recovery time in people with SCD and ACS.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
03/29/2013
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Anemia, Sickle Cell
Register for Updates
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
NCT01505088
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts +2 locations
Conditions: Anterior Uveitis
Register for Updates
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: Boston Floating Hospital Infants and Children, Boston, Massachusetts +2 locations
Conditions: Leukemia
Register for Updates
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT01266811
Withdrawn
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2013
Locations: Not set, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Leukemia, Myelocytic, Acute
Register for Updates
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
NCT00000801
Completed
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2012
Locations: Beth Israel Deaconess - West Campus, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
Corticosteroid Injection for Common Upper Extremity Problems
NCT00438672
Completed
The purpose of the study is to compare the effectiveness of a steroid injection to a placebo (inactive substance) in the treatment of lateral elbow pain, deQuervain's tendonitis, or base of the thumb carpometacarpal (CMC) arthritis. We are also trying to identify which personality factors and mindsets influence perceptions of elbow, wrist and hand pain. We hope to enroll 213 subjects in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2012
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lateral Elbow Pain
Register for Updates
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
NCT00621985
Completed
The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. We performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
01/26/2011
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Adrenal Hyperplasia, Congenital
Register for Updates
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
NCT00694135
Completed
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
08/27/2010
Locations: Ophthalmic Consultants of Boston, Boston, Massachusetts +1 locations
Conditions: Uveitis, Anterior
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates